Full metadata record
DC FieldValueLanguage
dc.creatorIrurzun-Arana, I. (Itziar)-
dc.creatorPrieto, E. (Eduardo)-
dc.creatorMartin-Algarra, S. (Salvador)-
dc.creatorTroconiz, I.F. (Iñaki F.)-
dc.date.accessioned2023-10-23T12:55:59Z-
dc.date.available2023-10-23T12:55:59Z-
dc.date.issued2020-
dc.identifier.citationIrurzun-Arana, I. (Itziar); Asín-Prieto, E. (Eduardo); Martin-Algarra, S. (Salvador); et al. "Predicting circulating biomarker response and its impact on the survival of advanced melanoma patients treated with adjuvant therapy". Scientific reports. 10 (1), 2020, 7478es
dc.identifier.issn2045-2322-
dc.identifier.urihttps://hdl.handle.net/10171/67700-
dc.description.abstractAdvanced melanoma remains a disease with poor prognosis. Several serologic markers have been investigated to help monitoring and prognostication, but to date only lactate dehydrogenase (LDH) has been validated as a standard prognostic factor biomarker for this disease by the American Joint Committee on Cancer. In this work, we built a semi-mechanistic model to explore the relationship between the time course of several circulating biomarkers and overall or progression free survival in advanced melanoma patients treated with adjuvant high-dose interferon-[Formula: see text]. Additionally, due to the adverse interferon tolerability, a semi-mechanistic model describing the side effects of the treatment in the absolute neutrophil counts is proposed in order to simultaneously analyze the benefits and toxic effects of this treatment. The results of our analysis suggest that the relative change from baseline of LDH was the most significant predictor of the overall survival of the patients. Unfortunately, there was no significant difference in the proportion of patients with elevated serum biomarkers between the patients who recurred and those who remained free of disease. Still, we believe that the modelling framework presented in this work of circulating biomarkers and adverse effects could constitute an additional strategy for disease monitoring in advance melanoma patients.es_ES
dc.language.isoenges_ES
dc.publisherSpringer Naturees_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectAdvanced melanomaes_ES
dc.subjectPoor prognosises_ES
dc.subjectSerologic markerses_ES
dc.subjectLactate dehydrogenase (LDH)es_ES
dc.titlePredicting circulating biomarker response and its impact on the survival of advanced melanoma patients treated with adjuvant therapyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.noteThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. Te images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.es_ES
dc.identifier.doi10.1038/s41598-020-63441-6-
dadun.citation.number1es_ES
dadun.citation.publicationNameScientific reportses_ES
dadun.citation.startingPage7478es_ES
dadun.citation.volume10es_ES
dc.identifier.pmid32366871-

Files in This Item:
Thumbnail
File
s41598-020-63441-6.pdf
Description
Size
2.78 MB
Format
Adobe PDF


Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.